- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 11
- States / cities
- Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more
- Conditions
- Fuchs Endothelial Dystrophy
- Interventions
- Netarsudil Ophthalmic Solution, Placebo
- Drug
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more